Evidence map›Paper›PMID 37085221›Full record

ReviewClinics in chest medicine2023

Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia.

Dayna McManus, Matthew W Davis, Alex Ortiz, Clemente Britto-Leon, Charles S Dela Cruz, Jeffrey E Topal

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in chest medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Dayna McManusDepartment of Pharmacy Services, Yale New Haven Hospital, 20 York Street, New Haven, CT 06510, USA. Electronic address: dayna.mcmanus@ynhh.org.
Matthew W DavisDepartment of Pharmacy Services, Yale New Haven Hospital, 20 York Street, New Haven, CT 06510, USA.
Alex OrtizPulmonary, Critical Care & Sleep Medicine, 300 Cedar Street, P.O. Box 208057, New Haven, CT 06520-8057, USA.
Clemente Britto-LeonPulmonary, Critical Care & Sleep Medicine, 300 Cedar Street, P.O. Box 208057, New Haven, CT 06520-8057, USA.
Charles S Dela CruzPulmonary, Critical Care & Sleep Medicine, 300 Cedar Street, P.O. Box 208057, New Haven, CT 06520-8057, USA.
Jeffrey E TopalDepartment of Pharmacy Services, Yale New Haven Hospital, 20 York Street, New Haven, CT 06510, USA. Electronic address: Jeffrey.Topal@ynhh.org.
Pulmonary and Critical Care Associates · USYale New Haven Hospital · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Morbidity and mortality from COVID-19 is due to severe inflammation and end-organ damage caused by a hyperinflammatory response. Multiple immunomodulatory agents to attenuate this response have been studied. Corticosteroids, specifically dexamethasone, have been shown to reduce mortality in hospitalized patients who require supplemental oxygen. Interleukin-6 antagonist, tocilizimab, and Janus kinase inhibitors have also been shown to reduce mortality. However, patients who have severe pulmonary end-organ damage requiring mechanical ventilation or extracorporeal membrane oxygenation appear not to benefit from immunomodulatory therapies. This highlights the importance of appropriate timing to initiate immunomodulatory therapies in the management of severe COVID-19 disease.

Indexed as

COVID-19PneumoniaHumansImmunomodulating AgentsLungSARS-CoV-2Immunomodulating AgentsCorticosteroidsCOVID-19Immunomodulatory treatmentJAK inhibitorsSARS-CoV-2

Identifiers

PMID37085221
PMCPMC9678826
OpenAlexW4309726422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.